SNORD24: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD24

NCBI ID: G26820

SNORD24

Other Name(s): Small nucleolar RNA, C/D box 24 | RNU24 | small nucleolar RNA, C/D box 24 | U24

SNORD24: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Introduction

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in eukaryotic cells. C/D box 24 (SNORD24) is a specific type of snRNA that is expressed in high levels in various tissues and cell types. The discovery of SNORD24 as a potential drug target and biomarker has significant implications for the development of new therapeutics for various diseases.

SNORD24 Functions as a Key Regulator of Chromatin Transcription

SnRNA are involved in the regulation of gene expression by binding to specific DNA sequences and affecting the loading of RNA polymerase II (RNA-protein complex) onto the DNA. SNORD24 is a member of the C/D box family of snRNAs, which are known for their ability to interact with specific DNA sequences in the 3'-end of pre-mRNA. The C/D box is a conserved region that is present in the 5'-end of many snRNAs and is involved in the formation of a specific type of base-pairing with DNA.

SNORD24 has been shown to play a role in regulating gene expression by binding to specific DNA sequences and affecting the loading of RNA-protein complexes

Protein Name: Small Nucleolar RNA, C/D Box 24

The "SNORD24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets